 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk [0m
[34mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: TIGECYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mID[0m[31m=[0m[31m"t11"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><caption [0m[31mID[0m[31m=[0m[31m"G27e24559[0m[31m-6ed6-49f7-a922-9571f94945ca"[0m[31m>Table [0m[1;31m10[0m[31m. Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mcaption[0m[31m><colgroup><col [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><[0m[31m/[0m[31mcolgroup[0m[31m><thead><tr><th/><th>Tigecycline for injection<[0m[31m/[0m[31mth[0m[31m><th>Levofloxacin<[0m[31m/[0m[31mth[0m[31m><th/><[0m[31m/[0m[31mtr[0m[31m><tr><th/><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m95[0m[31m% [0m
[31mCI<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tfoot><tr><td [0m[31mcolspan[0m[31m=[0m[31m"4"[0m[31m><sup>a<[0m[31m/[0m[31msup[0m[31m TIGECYCLINE: clinical_studies_table: > Patients at higher risk of death include patients with any one of the following: [0m
[31m&#x2265;[0m[1;31m50[0m[31m year of age; PSI score &#x2265;[0m[1;31m3[0m[31m; or bacteremia due to <content [0m[31mstyleCode[0m[31m=[0m[31m"italics"[0m[31m>Streptococcus pneumoniae<[0m[31m/[0m[31mcontent[0m[31m><paragraph><sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m95[0m[31m% confidence interval for the treatment [0m
[31mdifference<[0m[31m/[0m[31mparagraph[0m[31m><paragraph><sup>c<[0m[31m/[0m[31msup[0m[31m> After at least [0m[1;31m3[0m[31m days of intravenous therapy, a switch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtfoot[0m[31m><tbody><tr><td>Study [0m[1;31m1[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-20.8[0m[31m, [0m[1;31m7[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m7[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td>Study [0m[1;31m2[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials demonstrated an increase in all-cause mortality in [0m
[31mtigecycline for injection-treated patients compared to controls with a risk difference of [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this increase has not been established. An increase was also seen in a [0m
[31mmeta-analysis limited to the approved indications [0m[1;31m[[0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[1;31m][0m[31m. The greatest difference in mortality was seen in tigecycline for injection-treated patients with ventilator-associated [0m
[31mpneumonia. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Anaphylactic Reactions: have been reported with tigecycline for injection and may be life-threatening. Avoid use in patients with known hypersensitivity to tetracyclines. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m.[0m
[31mTIGECYCLINE: warnings_and_cautions: [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m Hepatic Adverse Effects: have been reported with tigecycline for injection. Patients who develop abnormal liver function tests during tigecycline for injection [0m
[31mtherapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Pancreatitis: including fatalities, has been reported [0m
[31mwith tigecycline for injection. If pancreatitis is suspected, then consider stopping tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Monitoring Blood Coagulation Parameters: Hypofibrinogenemia has been reported [0m
[31mwith tigecycline for injection. Monitor blood coagulation parameters, including fibrinogen, at baseline and regularly during treatment with tigecycline for injection. [0m[1;31m([0m[31m [0m[1;31m5[0m[31m. TIGECYCLINE: [0m
[31mwarnings_and_cautions: [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m Tooth Discoloration and Enamel Hypoplasia: The use of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and childhood to the age of [0m[1;31m8[0m[31m [0m
[31myears[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m and enamel hypoplasia. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m Inhibition of Bone Growth: The use of tigecycline for injection during the second and third [0m
[31mtrimester of pregnancy, infancy, and childhood up to the age of [0m[1;31m8[0m[31m years may cause reversible inhibition of bone growth. [0m[1;31m([0m[31m [0m[1;31m5.8[0m[31m [0m[1;31m)[0m[31m Clostridium difficile associated Diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m: evaluate if diarrhea [0m
[31moccurs. [0m[1;31m([0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m All-Cause Mortality An increase in all-cause mortality has been observed in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials in tigecycline for injection-treated patients versus [0m
[31mcomparator-treated patients. TIGECYCLINE: warnings_and_cautions: In all [0m[1;31m13[0m[31m Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m trials that included a comparator, death occurred in [0m[1;31m4.0[0m[31m% [0m[1;31m([0m[1;31m150[0m[31m/[0m[1;31m3788[0m[1;31m)[0m[31m of patients receiving tigecycline for [0m
[31minjection and [0m[1;31m3.0[0m[31m% [0m[1;31m([0m[1;31m110[0m[31m/[0m[1;31m3646[0m[1;31m)[0m[31m of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, the adjusted risk difference of all-cause [0m
[31mmortality was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m between tigecycline for injection and comparator-treated patients. An analysis of mortality in all trials conducted for approved indications [0m[1;31m([0m[31mcSSSI, cIAI, and [0m
[31mCABP[0m[1;31m)[0m[31m, including post-market trials showed an adjusted mortality rate of [0m[1;31m2.5[0m[31m% [0m[1;31m([0m[1;31m66[0m[31m/[0m[1;31m2640[0m[1;31m)[0m[31m for tigecycline and [0m[1;31m1.8[0m[31m% [0m[1;31m([0m[1;31m48[0m[31m/[0m[1;31m2628[0m[1;31m)[0m[31m for comparator, respectively. TIGECYCLINE: warnings_and_cautions: The [0m
[31madjusted risk difference for mortality stratified by trial weight was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this mortality difference has not been established. Generally, deaths were the result of [0m
[31mworsening infection, complications of infection or underlying co-morbidities. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable [0m[31m . [0m[1;31m5.2[0m[31m [0m
[31mMortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia A trial of patients with hospital acquired, including ventilator-associated, pneumonia failed to demonstrate the efficacy of [0m
[31mtigecycline for injection. TIGECYCLINE: warnings_and_cautions: In this trial, patients were randomized to receive tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg initially, then [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m or a [0m
[31mcomparator. In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who received tigecycline for injection had [0m
[31mlower cure rates [0m[1;31m([0m[1;31m47.9[0m[31m% versus [0m[1;31m70.1[0m[31m% for the clinically evaluable population[0m[1;31m)[0m[31m. In this trial, greater mortality was seen in patients with ventilator-associated pneumonia who received tigecycline for [0m
[31minjection [0m[1;31m([0m[1;31m25[0m[31m/[0m[1;31m131[0m[31m [0m[1;31m[[0m[1;31m19.1[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m15[0m[31m/[0m[1;31m122[0m[31m [0m[1;31m[[0m[1;31m12.3[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m [0m[31m . Particularly high mortality was seen among tigecycline for injection-treated patients with ventilator-associated [0m
[31mpneumonia and bacteremia at baseline [0m[1;31m([0m[1;31m9[0m[31m/[0m[1;31m18[0m[31m [0m[1;31m[[0m[1;31m50.0[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m1[0m[31m/[0m[1;31m13[0m[31m [0m[1;31m[[0m[1;31m7[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m7[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m. [0m[1;31m5.3[0m[31m Anaphylactic Reactions Anaphylactic reactions have been [0m
[31mreported with nearly all antibacterial agents, including tigecycline for injection, and may be life-threatening. Tigecycline for injection is structurally similar to tetracycline-class antibacterial [0m
[31mdrugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs. [0m[1;31m5.4[0m[31m Hepatic Adverse Effects Increases in total bilirubin concentration, prothrombin time [0m
[31mand transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with [0m
[31mtigecycline. Some of these patients were receiving multiple concomitant medications.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: boxed_warning: WARNING: ALL-CAUSE MORTALITY An increase in all-cause mortality has been observed in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials in tigecycline for [0m
[31minjection-treated patients versus comparator. The cause of this mortality risk difference of [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m has not been established. Tigecycline for injection should be reserved for use in [0m
[31msituations when alternative treatments are not suitable [0m[31m. WARNING: ALL-CAUSE MORTALITY See full prescribing information for complete boxed warning. All-cause mortality was higher in patients treated [0m
[31mwith tigecycline for injection than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of [0m[1;31m0[0m[31m. TIGECYCLINE: boxed_warning: [0m[1;31m6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m has not been [0m
[31mestablished. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable [0m[1;31m([0m[31m [0m[1;31m1.4[0m[31m , [0m[1;31m5.1[0m[31m , [0m[1;31m5.2[0m[31m , [0m[1;31m6.1[0m[31m [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: package_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: product_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: pharm_class_cs         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: clinical_studies: [0m[1;31m3[0m[1;31m)[0m[31m Legionella pneumophila [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m Streptococcus pneumoniae [0m[1;31m([0m[31mpenicillin-susceptible only[0m[1;31m)[0m[31m b [0m[1;31m44[0m[31m/[0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m95.7[0m[1;31m)[0m[31m [0m[1;31m39[0m[31m/[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m88.6[0m[1;31m)[0m[31m To further evaluate the [0m
[31mtreatment effect of tigecycline, a post-hoc analysis was conducted in CABP patients with a higher risk of mortality, for whom the treatment effect of antibacterial drugs is supported by historical [0m
[31mevidence. The higher-risk group included CABP patients from the two studies with any of the following factors: Age â‰¥[0m[1;31m50[0m[31m years PSI score â‰¥[0m[1;31m3[0m[31m Streptococcus pneumoniae bacteremia The results of this [0m
[31manalysis are shown in Table [0m[1;31m10[0m[31m. Age â‰¥[0m[1;31m50[0m[31m was the most common risk factor in the higher-risk group. Table [0m[1;31m10[0m[31m. TIGECYCLINE: clinical_studies: Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality a Tigecycline for injection Levofloxacin n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m95[0m[31m% CI b a Patients at higher risk of death include patients with any one of [0m
[31mthe following: â‰¥[0m[1;31m50[0m[31m year of age; PSI score â‰¥[0m[1;31m3[0m[31m; or bacteremia due to Streptococcus pneumoniae b [0m[1;31m95[0m[31m% confidence interval for the treatment difference c After at least [0m[1;31m3[0m[31m days of intravenous therapy, a [0m
[31mswitch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. Study [0m[1;31m1[0m[31m c CE Higher risk Yes [0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82.4[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m No [0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-20.8[0m[31m, [0m
[1;31m7[0m[31m. TIGECYCLINE: clinical_studies: [0m[1;31m1[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m [0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m No [0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77.6[0m[1;31m)[0m[31m [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8.7[0m[1;31m)[0m[31m Study [0m[1;31m2[0m[31m CE Higher risk Yes [0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88.8[0m[1;31m)[0m[31m [0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m [0m
[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m No [0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m [0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8.6[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m [0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m No [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Tigecycline has been associated with an increase in all-cause mortality compared to controls in a meta-analysis of Phase [0m[1;32m3[0m[32m and [0m[1;32m4[0m[32m clinical trials. The risk difference was [0m[1;32m0.6[0m[32m% [0m[1;32m([0m[1;32m95[0m[32m% CI [0m[1;32m0.1[0m[32m, [0m
[1;32m1.2[0m[1;32m)[0m[32m. The cause of this increase has not been established, and the greatest difference in mortality was seen in patients with ventilator-associated pneumonia. Tigecycline should be reserved for [0m
[32msituations when alternative treatments are not suitable.[0m

[32mSOURCE: TIGECYCLINE label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mincrease in all-cause mortality[0m[32m...[0m[32m [0m[1;32m0.6[0m[32m% [0m[1;32m([0m[1;32m95[0m[32m% CI [0m[1;32m0.1[0m[32m, [0m[1;32m1.2[0m[1;32m)[0m[32m...[0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Tigecycline has been associated with an [0m
[34mincrease in all-cause mortality compared to controls in a meta-analysis of Phase [0m[1;34m3[0m[34m and [0m[1;34m4[0m[34m clinical trials. The risk difference was [0m[1;34m0.6[0m[34m% [0m[1;34m([0m[1;34m95[0m[34m% CI [0m[1;34m0.1[0m[34m, [0m[1;34m1.2[0m[1;34m)[0m[34m. The cause of this increase has not been [0m
[34mestablished, and the greatest difference in mortality was seen in patients with ventilator-associated pneumonia. Tigecycline should be reserved for situations when alternative treatments are not [0m
[34msuitable.[0m

[34mSOURCE: TIGECYCLINE label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mincrease in all-cause mortality[0m[34m...[0m[34m [0m[1;34m0.6[0m[34m% [0m[1;34m([0m[1;34m95[0m[34m% CI [0m[1;34m0.1[0m[34m, [0m[1;34m1.2[0m[1;34m)[0m[34m...[0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that TIGECYCLINE has been associated with an increase in all-cause mortality compared to controls in a meta-analysis of Phase 3 and 4 clinical trials, with a risk [0m
[32mdifference of 0.6% [0m[32m([0m[32m95% CI 0.1, 1.2[0m[32m)[0m[32m. However, the cause of this increase has not been established, and the greatest difference in mortality was seen in patients with ventilator-associated pneumonia. [0m
[32mTigecycline should be reserved for situations when alternative treatments are not suitable."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"TIGECYCLINE has been associated with an increase in all-cause mortality compared to controls, with a risk difference of 0.6%. However, the specific risk regarding mortality after [0m
[32mmyocardial infarction is not detailed, and the cause of the increased mortality has not been established. The data indicates that the greatest difference in mortality was observed in patients with [0m
[32mventilator-associated pneumonia, not specifically post-myocardial infarction patients. Therefore, while there is an association with increased mortality, the direct impact on mortality specifically [0m
[32mafter myocardial infarction cannot be conclusively determined from the provided information."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does TIGECYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that TIGECYCLINE has been associated with an increase in all-cause mortality compared to controls in a meta-analysis of Phase 3 and 4 clinical trials, with a risk [0m
[34mdifference of 0.6% [0m[34m([0m[34m95% CI 0.1, 1.2[0m[34m)[0m[34m. However, the cause of this increase has not been established, and the greatest difference in mortality was seen in patients with ventilator-associated pneumonia. [0m
[34mTigecycline should be reserved for situations when alternative treatments are not suitable."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"TIGECYCLINE has been associated with an increase in all-cause mortality compared to controls, with a risk difference of 0.6%. However, the specific risk regarding mortality after [0m
[34mmyocardial infarction is not detailed, and the cause of the increased mortality has not been established. The data indicates that the greatest difference in mortality was observed in patients with [0m
[34mventilator-associated pneumonia, not specifically post-myocardial infarction patients. Therefore, while there is an association with increased mortality, the direct impact on mortality specifically [0m
[34mafter myocardial infarction cannot be conclusively determined from the provided information."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does TIGECYCLINE increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of mortality after myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that TIGECYCLINE has been associated with an increase in all-cause mortality compared to controls in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials, with a risk difference of[0m
[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. However, the cause of this increase has not been established, and the greatest difference in mortality was seen in patients with ventilator-associated pneumonia. Tigecycline [0m
[31mshould be reserved for situations when alternative treatments are not suitable.[0m
[31m        -----[0m
[31m        Final answer: TIGECYCLINE has been associated with an increase in all-cause mortality compared to controls, with a risk difference of [0m[1;31m0.6[0m[31m%. However, the specific risk regarding mortality after[0m
[31mmyocardial infarction is not detailed, and the cause of the increased mortality has not been established. The data indicates that the greatest difference in mortality was observed in patients with [0m
[31mventilator-associated pneumonia, not specifically post-myocardial infarction patients. Therefore, while there is an association with increased mortality, the direct impact on mortality specifically [0m
[31mafter myocardial infarction cannot be conclusively determined from the provided information.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge. The response appropriately conveys the strength of evidence and the [0m
[32mmagnitude of the effect, noting the lack of specific information about the risk of mortality after myocardial infarction. The answer is well-reasoned and does not contain identifiable flaws."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge. The response appropriately conveys the strength of evidence and the [0m
[34mmagnitude of the effect, noting the lack of specific information about the risk of mortality after myocardial infarction. The answer is well-reasoned and does not contain identifiable flaws."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge. The response appropriately conveys the strength of evidence and the [0m
[31mmagnitude of the effect, noting the lack of specific information about the risk of mortality after myocardial infarction. The answer is well-reasoned and does not contain identifiable flaws.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does TIGECYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m is that TIGECYCLINE has been associated with an increase in all-cause [0m
[32mmortality compared to controls, with a risk difference of [0m[1;32m0.6[0m[32m%. However, the specific risk regarding mortality after myocardial infarction is not detailed, and the cause of the increased mortality has[0m
[32mnot been established. The data indicates that the greatest difference in mortality was observed in patients with ventilator-associated pneumonia, not specifically post-myocardial infarction patients. [0m
[32mTherefore, while there is an association with increased mortality, the direct impact on mortality specifically after myocardial infarction cannot be conclusively determined from the provided [0m
[32minformation.[0m
